Рыночные новости
Заголовки по акциям и крипте из Alpaca. Храним 7 дней. Всего: 9756.
-
Nurix Therapeutics Announces Sanofi's Decision to Discontinue SAR448272 ProgramSanofi has notified Nurix Therapeutics of its decision to terminate the Phase 1 clinical trial and development program for the oral STAT6 degrader SAR448272.
-
Arcus Biosciences Scheduled to Report Third Quarter 2026 Financial ResultsArcus Biosciences, Inc. is scheduled to release its financial results for the third quarter of 2026 on November 4, 2026, after the market closes.
-
Addus HomeCare Reports Q3 2026 Financial ResultsAddus HomeCare Corporation reported its third-quarter 2026 financial results, featuring an adjusted EPS of $1.83 and revenue of $387.7 million.
-
Needham Maintains Buy Rating on nLIGHT, Lowers Price Target to $50Needham has reaffirmed its 'Buy' rating on nLIGHT, Inc. while adjusting its price target from $90 to $50.
-
LTC Properties Reports 2026 Third Quarter ResultsLTC Properties, Inc. announced its operating results for the third quarter ended September 30, 2026.
-
The Andersons, Inc. Announces Third Quarter 2026 Financial ResultsThe Andersons, Inc. reported record third quarter net income of $46 million, or $1.36 per diluted share, for the period ended September 30, 2026.
-
Seadrill Limited Reports Q3 2026 Financial Results and Raises Full-Year GuidanceSeadrill Limited reported third-quarter revenue of $428.0 million, exceeding analyst expectations, while also increasing its full-year 2026 guidance.
-
AtriCure Reports Third-Quarter 2026 Financial ResultsAtriCure announced its Q3 2026 financial results, reporting $154.5 million in revenue and $4.1 million in net income.
-
Fortive Senior Vice President and Chief Legal Officer Sells SharesPeter C. Underwood, Senior Vice President and Chief Legal Officer of Fortive, sold 48,442 shares of company stock on October 30, 2026.
-
UFP Technologies Reports Third Quarter 2026 Financial ResultsUFP Technologies, Inc. reported net income of $20.6 million for the third quarter ended September 30, 2026, representing a 25.8% increase compared to the same period in 2025.
-
Scotiabank Upgrades Ero Copper to Sector OutperformScotiabank upgraded Ero Copper Corp. from Sector Perform to Sector Outperform while adjusting its price target.
-
Triple Flag Precious Metals Corp. Reports Third Quarter 2026 Financial ResultsTriple Flag Precious Metals Corp. announced its financial results for the third quarter of 2026, reporting $106.7 million in revenue and declaring a quarterly dividend of US$0.06 per share.
-
Citigroup Adjusts Eastman Chemical Price TargetCitigroup has revised its price target for Eastman Chemical Company, lowering it from $76.00 to $75.00 per share.
-
Globus Medical Completes Acquisition of Synaptive MedicalGlobus Medical, Inc. announced the completion of its acquisition of Synaptive Medical, a company specializing in cranial neurosurgery technologies.
-
The Trade Desk Strengthens Leadership Bench, Expands Engagement with Dave PicklesThe Trade Desk announced that co-founder and former CTO Dave Pickles is returning to the company in an expanded technology leadership capacity to guide its product and engineering roadmap.
-
Bel Fuse Reports Third-Quarter 2026 Financial ResultsBel Fuse reported third-quarter 2026 revenue of $220.5 million, representing a 23.2% increase compared to the same period in the prior year.
-
Par Pacific Holdings, Inc. Reports Third Quarter 2026 Financial ResultsPar Pacific reported strong third-quarter 2026 financial results, including net income of $353.3 million and Adjusted EBITDA of $646.0 million, bolstered by small refinery exemption benefits.
-
Talos Energy Inc. Reports Third Quarter 2026 Financial and Operational ResultsTalos Energy announced its Q3 2026 financial results, exceeding production guidance and providing an update to its full-year 2026 outlook.
-
Northern Oil and Gas, Inc. Declares Quarterly DividendNorthern Oil and Gas, Inc. has declared a quarterly cash dividend of $0.45 per share.
-
Lirafugratinib (Lyrfigtu™) Added to NCCN Clinical Practice GuidelinesElevar Therapeutics, which holds an exclusive license for lirafugratinib from Relay Therapeutics, announced the drug's inclusion in the NCCN Clinical Practice Guidelines.